Join Us

We are 224,436 members in 83 forums discussing 163,550 topics.

Help with Abbreviations

Topic: Enhertu shows Kadcyla Who’s Boss in HER2+ MBC / DESTINY 03

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Sep 20, 2021 01:02AM - edited Sep 20, 2021 01:03AM by Olma61

Olma61 wrote:

“Enhertu slashed the risk of disease progression or death by a massive 71.6% over Kadcyla in second-line HER2-positive metastatic breast cancer patients previously treated with Roche's Herceptin and chemo, AstraZeneca and Daiichi reported at the European Society for Medical Oncology 2021 virtual meeting.

“The showing is so impressive that the study authors concluded that the study, dubbed Destiny-Breast03, will lead to a paradigm shift in the treatment of HER2-positive breast cancer."

They're so excited that they're saying the C-Word after seeing the results of this trial -

“In Destiny-Breast03, Enhertu also more than doubled the number of patients who responded to treatment, as the AZ-Daiichi med shrunk tumors in about 8 of 10 its patients, while the rate for Kadcyla was just a little over one third.

"The investigators that we talked to start talking about maybe we're opening up the possibility for some women that a cure could be possible in advance disease," Fredrickson said.

10/30/2017 Xgeva for bone mets 5/31/2018 Taxol finished! "If one just keeps on walking, everything will be all right” - Kierkegaard Dx 8/3/2017, IDC, Right, 2cm, Stage IV, metastasized to bone, Grade 2, ER+/PR+, HER2+ (IHC) Targeted Therapy 10/28/2017 Perjeta (pertuzumab) Targeted Therapy 10/28/2017 Herceptin (trastuzumab) Chemotherapy 10/30/2017 Taxol (paclitaxel) Hormonal Therapy 5/14/2018 Arimidex (anastrozole) Radiation Therapy 5/30/2019 External: Bone
Log in to post a reply